Both BPC-157 and TB-500 are currently under review by the FDA's Pharmacy Compounding Advisory Committee (PCAC) , with a formal advisory panel evaluation scheduled for July 2324, 2026
ukasik J, Salminen S, Szajewska H
Propanediol, 1,2-Hexanediol, Glycerin, Hydroxyacetophenone, Betaine, Mineral Salt, Panthenol , Ethylhexylglycerin, Sodium Polyacryloyldimethyl Taurate, Disodium EDTA, Butylene Glycol, Salix Alba (Willow) Bark Extract, Castanea Crenata Shell Extract, Lavandula Angustifolia (Lavender) Flower Extract, Hyaluronic Acid, Hydrolyzed Hyaluronic Acid, Sodium Hyaluronate, Allatoin, Citric Acid, Capryloyl Salicylic Acid, Gluconolactone, Sodium Citrate, Salicylic Acid, Glycolic Acid, etc
Research-grade compounds are not manufactured to pharmaceutical standards, are not subject to quality testing requirements, and carry unknown purity risks
Evidence for direct cellular protective effect of PL-10 substances (synthesized parts of body protective compound, BPC) and their specificity to gastric mucosal cells